Eton Pharmaceuticals Licenses U.S. Rights To Rare Disease Product Candidate ASN-001 From Auson Pharmaceuticals For Treatment Of Proliferating Superficial Infantile Hemangiomas
ASN-001 targets the substantially larger population of moderate infantile hemangiomas currently treated off-label with topical timololComplementary product to HEMANGEOL® (propranolol hydrochloride) oral solution,
Eton Pharmaceuticals got the right to sell a new medicine for a specific childhood skin condition in the United States. This shows the company is growing its medicine lineup, which could help them serve more patients and make more money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.